Aragon
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Major prostate cancer screening trial launched in UK
The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men
J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis
The drug is the first IL-23 inhibitor approved for children from the age of six
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer
An estimated 84,870 people will be diagnosed with bladder cancer in the US this year
Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer
Around 55,100 cases of prostate cancer are diagnosed in the UK every year
FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis
The Stelara biosimilar now offers all dosage forms and strengths of its reference product
J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis
The inflammatory condition affects approximately 30% of psoriasis patients